Key Highlights

  • Eloxx Pharmaceuticals returned to Nasdaq trading in June 2026 after a $66 million offering, less than three years after being delisted, transforming its cash position from $6.4 million to nearly $62 million.
  • The FDA cleared a Phase 2b trial of lead candidate exaluren in nonsense mutation Alport syndrome, a rare kidney disease, with the first US site now enrolling patients and more activating through the autumn.
  • Cash on hand is guided to fund operations into mid-2028, covering both the Alport syndrome readout and the start of a second kidney disease trial without requiring a return to capital markets.

Few micro-cap biotechs get a second act as clean as the one Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has written. Less than three years after Nasdaq removed it from the exchange, the shares trade on the Nasdaq Capital Market again, the Balance Sheet holds about $62 million, and the lead drug is being given to patients in a placebo-controlled trial the US Food and Drug Administration cleared this year.

The contrast with early 2026 is stark. In its registration statement filed on 7 May, Eloxx disclosed $6.4 million of cash at 31 March, a $7.6 million Working Capital deficit, an accumulated Deficit of $304.3 million and substantial doubt about its ability to continue as a going concern. It had been so short of capital after the delisting that it could not file annual reports for fiscal 2023 and 2024 until funding arrived in August 2025.

The second-quarter report published on 12 August 2026 is the first full accounting since that reset. Two Brokers initiated coverage in July, and the shares closed at $19.07 on 13 August, above June's $11.00 offering price.

What Happened

Eloxx filed a Form 8-K on 11 August 2026 and issued its second-quarter release the next day. The headline item was cash: $61.96 million at 30 June, against $4.79 million at 31 December 2025. Management said that should fund operations into mid-2028, with no outstanding debt.

The money came from an offering priced on 8 June and bookrun by Leerink Partners and Guggenheim Securities. Eloxx sold 2,975,000 shares at $11.00 plus pre-funded warrants covering 3,025,000 more at $10.99, raising $66.0 million gross and $58.3 million net. The stock began trading on Nasdaq on 9 June.

Clinically, the FDA cleared the Phase 2b study of exaluren in nonsense mutation Alport syndrome, with initiation planned for the third quarter. That study, branded EXACT and registered as NCT07523581, already has an open site: the Alport Syndrome Foundation's July newsletter named Colorado Kidney Care in Denver as recruiting, with more US sites activating this autumn.

Why It Matters

Alport syndrome is an inherited kidney disease caused by faults in COL4A3, COL4A4 and COL4A5, the genes encoding collagen IV, the structural protein of the kidney's filtering membrane. Patients typically reach kidney failure in their twenties or thirties.

Exaluren targets a specific subset. A nonsense mutation inserts a premature stop signal into a gene, so the cell halts protein assembly early and makes a truncated, useless collagen chain. Exaluren is a small molecule designed to modulate the ribosome, the cell's protein-making machine, and promote readthrough of those premature stop codons so full-length protein can be produced. Eloxx says roughly 7% of Alport patients carry such mutations, and that this group reaches kidney failure at a mean age of 20.4 years.

Exaluren holds Orphan Drug designation from the FDA and the European Commission in Alport syndrome, and the Commission added orphan status in autosomal dominant polycystic kidney disease (ADPKD) in July 2026. Eloxx retains global rights to both kidney programmes.

The Numbers

Spending is rising as the pipeline restarts. Research and Development cost $2.84 million in the second quarter against $0.90 million a year earlier; administrative expenses were $1.61 million versus $0.68 million. Net loss widened to $4.50 million from $1.89 million, or $(0.66) per share against $(5.45), on weighted average shares of 6,789,165 versus 347,000. Six-month net loss was $8.26 million.

Shareholders' Equity stood at $46.42 million at 30 June, a swing from a $11.91 million deficit at end-2025.

The share count was reworked by a one-for-eleven reverse split in May 2026, with all per-share figures restated. Quoted Market Capitalisation sat near $77 million on 13 August, excluding several million shares issuable under pre-funded warrants priced at $0.01 to $0.11. Guggenheim's Vamil Divan initiated at Buy with a $43 target on 20 July, and LifeSci Capital's Rami Katkhuda at Outperform with a $40 target on 22 July.

What It Means for the Company

Eloxx has moved from a survival problem to an execution problem. A runway into mid-2028 covers the Alport readout schedule and the start of the ADPKD study without a return to the market, which is unusual for a company this size.

It also gives two shots at the same biology: if readthrough restores collagen IV in Alport kidneys, the identical mechanism applies to PKD1 and PKD2 nonsense mutations in ADPKD, a far larger indication. A third asset, ZKN-013, is out-licensed to Spain's Almirall, S.A. for rare blistering skin diseases and is in Phase 1, with Eloxx eligible for up to roughly $470 million in milestones plus tiered royalties.

Risks Investors Should Watch

The central risk is that exaluren has not yet produced randomised efficacy data. EXACT is a double-blind, placebo-controlled, delayed-start study in patients aged 12 and over with a confirmed nonsense mutation, running about 42 weeks per participant. Until the placebo comparison reads out, the mechanism stays unproven in a controlled setting.

Enrolment is a real constraint: the eligible population is a rare mutation type within an already rare disease, and only one US site was confirmed open in July.

Dilution deserves attention. Beyond the new pre-funded warrants, the May prospectus listed 4,958,919 shares under existing pre-funded warrants exercisable at $0.11 and 879,146 option shares at a weighted average $12.17.

The listing history is recent too. Nasdaq removed Eloxx on 16 October 2023 for failing Listing Rule 5550(b)(2), which requires a $35 million minimum Market Value of listed securities, and the stock spent the interim on the OTC Expert Market.

What Comes Next

The nearest checkpoint is site activation and enrolment in EXACT through the second half of 2026. Eloxx has guided to topline data from the initial 16-week placebo-controlled portion by mid-2027, and the final readout by end-2027.

The ADPKD Phase 2 is planned for 2027 with topline data by mid-2028. Third-quarter results are due in the autumn, and Almirall's Phase 1 progress on ZKN-013 could trigger milestones.

Conclusion

Eloxx has executed about as clean a second act as a Delisted micro-cap biotech can manage, going from a $7.6 million working capital deficit and going-concern language to $62 million in cash and two analyst initiations within months. That transformation solves the company's funding problem but not its scientific one: exaluren has not yet produced randomized, placebo-controlled efficacy data, and the eligible patient population, carriers of a specific rare mutation within an already rare disease, is small enough that enrollment pace will matter as much as biology. The mid-2027 initial readout from the EXACT trial's placebo-controlled portion is the milestone that will determine whether this turnaround extends into a validated therapy.